Psoriasis Clinical Trial
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Summary
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.
Eligibility Criteria
Inclusion Criteria:
Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
Women must not be pregnant, lactating, or breastfeeding
Exclusion Criteria:
Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
How clear is this clinincal trial information?